Abiopharma

PRECISION BIOSCIENCES INC (DTIL) Reports the reporting period Financial Results PRECISION BIOSCIENCES INC (DTIL) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 10838
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 125847
  • targeting of the root cause of the disease; the design of PBGENE-DMD to improve function over time and address more than 60% of patients with DMD; the potential for PBGENE-DMD to provide durable functional improvement with a single dose of AAV; translation of results in preclinical studies of ARCUS nucleases to clinical studies in humans; the preclinical and clinical development and demonstrated, potential and expected safety, efficacy, durability, and benefit of PBGENE-HBV and PBGENE-DMD, as well as our other product candidates and those being developed by partners; expectations of additional data presentations by IECURE from the ongoing OTC-HOPE clinical trial at ASGCT and SIMD; expectations of a presentation by Imugene Limited from their azer-cel clinical trial at ASCO; expectations of TG Therapeutics to present preliminary Phase 1 azer-cel data in progressive multiple sclerosis in the second half of 2026
  • expected in the second quarter of 2026
  • targeting the elimination of cccDNA leading to sustained loss of HBV DNA. The FDA has previously provided guidance that sustained loss of HBV DNA is an approvable endpoint for chronic hepatitis B.Further details on the trial can be found on Precision’s website and on clinicaltrials.gov identifier NCT0668